Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.
Blood Adv. 2023 May 23;7(10):2042-2046. doi: 10.1182/bloodadvances.2022008245.
Advances in treatment have reduced mortality from Hodgkin lymphoma; therefore, greater attention should be focused on minimizing the late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation but not patient-specific comorbidities. Herein, we describe a patient with sickle cell disease diagnosed with Hodgkin lymphoma and the considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient's preexisting sickle cell disease complications.
治疗的进展降低了霍奇金淋巴瘤的死亡率；因此，应更加关注将晚期影响降至最低。存在多种风险适应性治疗方案，这些方案侧重于疾病表现，而不是患者特有的合并症。在此，我们描述了一例患有镰状细胞病的霍奇金淋巴瘤患者，并描述了在治疗计划中为降低与患者先前镰状细胞病并发症重叠的治疗相关急性毒性和晚期影响而进行的考虑。
Zotero 插件